Business Wire

VEEVA-SYSTEMS

Share
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications

Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging biotechs and enterprise companies, including 12 of the top 20 global pharmaceutical companies, are modernizing submission planning, tracking, and publishing to stay ahead of evolving regulations, including the ISO IDMP standards.

“Streamlining regulatory processes is a strategic priority to support efficient submission planning and execution and get medicines to patients faster,” said Dominique Lagrave, head, global regulatory operations at Amgen. “Veeva Vault RIM will unify regulatory processes and deliver the visibility we need to make faster, more informed decisions.”

Life sciences companies of all sizes are rapidly adopting Vault RIM applications to simplify management for product registrations, submission documents, published dossiers, and health authority interactions. Vault RIM removes the reliance on spreadsheets and manual processes so regulatory teams can get the right information to the right person at the right time.

Organizations are leveraging Vault Registrations to support IDMP standards with new entities to better track, manage, and link registered product data. Users can also get a complete view into IDMP data sets based on a product’s current registered details and capture IDMP elements throughout the regulatory process. Now regulatory teams can simplify IDMP implementation for improved quality and compliance.

“More companies are partnering with Veeva to keep pace with changing regulations and bring products to market faster,” said John Lawrie, vice president, Veeva Vault RIM. “Veeva Vault RIM delivers the scale to author and publish thousands of change requests and the innovation to seamlessly manage regulations like IDMP.”

The Veeva Vault RIM Suite includes Vault Registrations , Vault Submissions , Vault Submissions Publishing , and Vault Submissions Archive for unified RIM capabilities on one cloud platform. Vault RIM is part of Veeva Development Cloud , a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive business processes across R&D and manufacturing.

Watch on-demand Veeva R&D and Quality Summit sessions at veeva.com/Summit to learn how leading companies partner with Veeva to transform regulatory information management.

Additional Information

For more on Veeva Vault RIM, visit: veeva.com/RIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Social Media:

https://www.facebook.com/VeevaSystems

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 06:00:00 CEST | Press release

Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye